IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC) Meeting Abstract
| Authors: | Dent, R.; Kim, S. B.; Oliveira, M.; Isakoff, S. J.; Barrios, C. H.; O'Shaughnessy, J.; Lu, X.; Wongchenko, M.; Bradley, D.; Mani, A.; Baselga, J.; Turner, N. C. |
| Abstract Title: | IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 63s |
| Language: | English |
| ACCESSION: | WOS:000442916007534 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.TPS1117 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS1117 -- Source: Wos |
